Cane Capital Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.08M Buy
3,398
+26
+0.8% +$26.6K 1.61% 18
2026
Q1
$3.1M Buy
3,372
+965
+40% +$978K 1.35% 18
2025
Q4
$2.59M Buy
+2,407
New +$2.3M 1.02% 24

Other funds holding LLY

Cane Capital Partners's LLY Position: Q2 2026 in Review

Cane Capital Partners increased its Eli Lilly (LLY) stake by 0.77% in Q2 2026, buying an estimated $26.6K and bringing the position to 3,398 shares worth $4.08M. The position accounts for 1.61% of the portfolio, ranked #18.

Cane Capital Partners first reported a position in LLY in Q4 2025 and has held it in 3 quarters since. 4,594 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Cane Capital Partners held 3,398 shares of Eli Lilly worth $4.08M as of Q2 2026.
  • Cane Capital Partners bought 26 Eli Lilly shares in Q2 2026, an estimated $26.6K.
  • Eli Lilly made up 1.61% of Cane Capital Partners's portfolio in Q2 2026, its #18 holding.
  • Cane Capital Partners first reported a position in Eli Lilly in Q4 2025 and has held it in 3 quarters since.
  • 4,594 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Cane Capital Partners's 13F filing for Q2 2026, filed 5 Aug 2026.